Common Contracts
4 similar Investors’ Rights Agreement contracts by Boundless Bio, Inc., Monte Rosa Therapeutics, Inc., Vera Therapeutics, Inc., Vividion Therapeutics, Inc.
AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT BOUNDLESS BIO, INC. April 5, 2023Investors’ Rights Agreement • September 1st, 2023 • Boundless Bio, Inc. • Pharmaceutical preparations • Delaware
THIS AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT (this “Agreement”), is made as of April 5, 2023, by and among Boundless Bio, Inc. a Delaware corporation (the “Company”), and each of the investors listed on Schedule A hereto, each of which is referred to in this Agreement as an “Investor”.
SECOND AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENTInvestors’ Rights Agreement • April 23rd, 2021 • Vera Therapeutics, Inc. • Pharmaceutical preparations • Delaware
THIS SECOND AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT (this “Agreement”), is made as of October 29, 2020, by and among Vera Therapeutics, Inc., a Delaware corporation formerly known as Trucode Gene Repair, Inc., (the “Company”), and each of the investors listed on Schedule A hereto, each of which is referred to in this Agreement as an “Investor”.
VIVIDION THERAPEUTICS, INC. THIRD AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENTInvestors’ Rights Agreement • April 23rd, 2021 • Vividion Therapeutics, Inc. • Pharmaceutical preparations • Delaware
THIS THIRD AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT (this “Agreement”), is made and entered into as of February 18, 2021, by and among VIVIDION THERAPEUTICS, INC., a Delaware corporation (the “Company”), and each of the investors listed on Schedule A hereto (each an “Investor” and together the “Investors”), each of the stockholders listed on Schedule B hereto, each of whom is referred to herein as a “Key Holder,” and The Scripps Research Institute, a California nonprofit public benefit corporation (“TSRI”), solely for purposes of Section 4 of this Agreement (for the avoidance of doubt, TSRI shall not be entitled to any other benefits pursuant to this Agreement other than those provided in Section 4 of this Agreement).
SECOND AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENTInvestors’ Rights Agreement • April 19th, 2021 • Monte Rosa Therapeutics, Inc. • Biological products, (no disgnostic substances) • Delaware
THIS SECOND AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT (this “Agreement”), is made as of the 11th day of March, 2021, by and among Monte Rosa Therapeutics, Inc., a Delaware corporation (the “Company”), each of the investors listed on Schedule A hereto, each of which is referred to in this Agreement as an “Investor.”
